DexCom, Inc. (DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
DexCom is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- It's been growing faster than most other healthcare companies over the past year.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally…
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 11,000
- Headquarters
- San Diego, CA
Similar stocks
What’s behind the score
Valuation
P/E 34.1 — lower than 46% of Healthcare peers
P/B 12.4 — lower than 18% of Healthcare peers
P/S 6.5 — lower than 23% of Healthcare peers
EV/EBITDA 22.7 — lower than 23% of Healthcare peers
EV/Revenue 6.4 — lower than 37% of Healthcare peers
PEG 2.1 — lower than 22% of Healthcare peers
FCF yield 3.1% — higher than 31% of Healthcare peers
Profitability & quality
Gross margin 62.5% — higher than 50% of Healthcare peers
Operating margin 24.3% — higher than 53% of Healthcare peers
Net margin 20.1% — higher than 80% of Healthcare peers
ROE 38.5% — higher than 85% of Healthcare peers
ROA 10.3% — higher than 69% of Healthcare peers
Free cash flow is 102% of reported net income
Financial health
Debt/equity 0.5 — lower than 70% of Healthcare peers
Current ratio 1.73 — higher than 69% of Healthcare peers
Quick ratio 1.37 — higher than 79% of Healthcare peers
Cash/debt 1.39 — higher than 83% of Healthcare peers
Debt/EBITDA 1.00 — lower than 79% of Healthcare peers
Growth
Revenue growth 13.1% YoY — higher than 80% of Healthcare peers
Earnings growth 43.6% YoY — higher than 73% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider selling, -6.8% of insider shares
Institutions net sold, -15.9% of shares held
Insiders hold 0.3% of shares outstanding
4.3% of float sold short
Momentum
Mixed vs its moving averages
83% of the way from its 52-week low to high